CoChat

Levodopa-carbidopa intestinal gel in advanced Parkinson's: Final results of the GLORIA registry

Open access
Antonini, Angelo, Poewe, Werner, Chaudhuri, K. Ray, Jech, Robert, Pickut, Barbara, Pirtošek, Zvezdan, Szasz, Jozsef, Valldeoriola, Francesc, Winkler, Christian, Bergmann, Lars, Yegin, Ashley, Onuk, Koray, Barch, David, Odin, Per, Amalia, Ene, Arnold, Guy, Bajenaru, Ovidiu, Bergmans, Bruno, Bjornara, Kari Anne, Blackie, Jeff, Bode, Matthias, Bourgeois, Paul, Bohlhalter, Stephan, Buraga, Ioan, Burkhard, Pierre R., Busson, Philippe, Calopa, Matilde, Clausen, Jesper, Danielsen, Erik Hvid, Defebvre, Luc, Delvaux, Valerie, Dethy, Sophie, Dietrichs, Espen, De Fabregues, Oriol, Gerhard, Ransmayr, Gusmaroli, Graziano, Hahn, Kirsten, Hauptmann, Björn, Henriksen, Tove, Hernandez-Vara, Jorge, Jeanjean, A., Kaiserova, Michaela, Kassubek, Jan, Kimber, Thomas, Konitsiotis, Spyridon, Krüger, Rejko, Kulisevsky, Jaime, Leenders, Jo, Lundqvist, Christofer, Ory Magne, F., Marano, Pietro, Milanov, Ivan, Modugno, Nicola, Misbahuddin, Anjum, Nevrly, Martin, Panayiotis, Zikos, Pedersen, Kenn Freddy, Pedersen, Stephen W., Perju-Dumbrava, Lacramioara, Ponsen, M.M., Popescu, Bogdan O., Rijntjes, Michel, Puente, V., Redecker, Christoph, Schrader, Christoph, Sensi, Mariachiara, Simu, Mihaela, Spanaki, Cleanthe, Storch, Alexander, Storstein, Anette, Tomantschger, Volker, van der Linden, Chris, van Laar, T., Viallet, F., Witjas, Tatiana, Wolz, Martin, Zibetti, Maurizio, Van Zandijcke, Michel · 2017 · Parkinsonism & Related Disorders
Cited by 220

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

INTRODUCTION: This registry evaluated the 24-month safety and efficacy of levodopa-carbidopa intestinal gel (LCIG) treatment in advanced Parkinson's disease (PD) patients under routine clinical care. METHODS: Motor fluctuations, dyskinesia, non-motor symptoms, quality of life, and safety were evaluated. Observations were fully prospective for treatment-naïve patients (60% of patients) and partially retrospective for patients with ≤12 months of pre-treatment with LCIG (40% of patients). Hours of "On" and "Off" time were assessed with a modified version of the Unified Parkinson's Disease Rating Scale part IV items 32 and 39. RESULTS: Overall, 375 patients were enrolled by 75 movement disorder centers in 18 countries and 258 patients completed the registry. At 24 months LCIG treatment led to significant reductions from baseline in "Off" time (hours/day) (mean ± SD = -4.1 ± 3.5, P < 0.001), "On" time with dyskinesia (hours/day) (-1.1 ± 4.8, P = 0.006), Non-Motor Symptom Scale total (-16.7 ± 43.2, P < 0.001) and individual domains scores, and Parkinson's Disease Questionnaire-8 item total score (-7.1 ± 21.0, P < 0.001). Adverse events deemed to have a possible/probable causal relationship to treatment drug/device were reported in 194 (54%) patients; the most frequently reported were decreased weight (6.7%), device related infections (5.9%), device dislocations (4.8%), device issues (4.8%), and polyneuropathy (4.5%). CONCLUSIONS: LCIG treatment led to sustained improvements in motor fluctuations, non-motor symptoms particularly sleep/fatigue, mood/cognition and gastrointestinal domains, as well as quality of life in advanced PD patients over 24 months. Safety events were consistent with the established safety profile of LCIG.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.parkreldis.2017.09.018

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 220

Metadata

Authors
Antonini, A., Poewe, W., Chaudhuri, K. R., Jech, R., Pickut, B., Pirtošek, Z., Szasz, J., Valldeoriola, F., Winkler, C., Bergmann, L., Yegin, A., Onuk, K., Barch, D., Odin, P., Amalia, E., Arnold, G., Bajenaru, O., Bergmans, B., Bjornara, K. A., Blackie, J., Bode, M., Bourgeois, P., Bohlhalter, S., Buraga, I., Burkhard, P. R., Busson, P., Calopa, M., Clausen, J., Danielsen, E. H., Defebvre, L., Delvaux, V., Dethy, S., Dietrichs, E., De Fabregues, O., Gerhard, R., Gusmaroli, G., Hahn, K., Hauptmann, B., Henriksen, T., Hernandez-Vara, J., Jeanjean, A., Kaiserova, M., Kassubek, J., Kimber, T., Konitsiotis, S., Krüger, R., Kulisevsky, J., Leenders, J., Lundqvist, C., Ory Magne, F., Marano, P., Milanov, I., Modugno, N., Misbahuddin, A., Nevrly, M., Panayiotis, Z., Pedersen, K. F., Pedersen, S. W., Perju-Dumbrava, L., Ponsen, M. M., Popescu, B. O., Rijntjes, M., Puente, V., Redecker, C., Schrader, C., Sensi, M., Simu, M., Spanaki, C., Storch, A., Storstein, A., Tomantschger, V., van der Linden, C., van Laar, T., Viallet, F., Witjas, T., Wolz, M., Zibetti, M., & Van Zandijcke, M.
Venue
Parkinsonism & Related Disorders
Publisher
Elsevier BV
Published
2017-12
Volume
45
Pages
13-20
ISSN
1353-8020 (ISSN-L)
OpenAlex
W2757488384
Cited by
220
References
1
FWCI
9.76
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Levodopa-carbidopa intestinal gel in advanced Parkinson's: Final results of the GLORIA registry. https://app.cochat.ai/papers/10.1016/j.parkreldis.2017.09.018
The paper
Antonini, A., Poewe, W., Chaudhuri, K. R., Jech, R., Pickut, B., Pirtošek, Z., Szasz, J., Valldeoriola, F., Winkler, C., Bergmann, L., Yegin, A., Onuk, K., Barch, D., Odin, P., Amalia, E., Arnold, G., Bajenaru, O., Bergmans, B., Bjornara, K. A., . . . Van Zandijcke, M. (2017). Levodopa-carbidopa intestinal gel in advanced Parkinson's: Final results of the GLORIA registry. Parkinsonism & Related Disorders. https://doi.org/10.1016/j.parkreldis.2017.09.018

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.